Hebei Changshan Biochem Pharma - Asset Resilience Ratio

Latest as of March 2024: -0.03%

Hebei Changshan Biochem Pharma (300255) has an Asset Resilience Ratio of -0.03% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hebei Changshan Biochem Pharma short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥-1.20 Million

≈ $-175.21K USD Cash + Short-term Investments

Total Assets

CN¥4.67 Billion

≈ $683.39 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Hebei Changshan Biochem Pharma's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300255 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Hebei Changshan Biochem Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Hebei Changshan Biochem Pharma (300255) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥-1.20 Million	-0.03%
Total Liquid Assets	CN¥-1.20 Million	-0.03%

Asset Resilience Insights

Limited Liquidity: Hebei Changshan Biochem Pharma maintains only -0.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Hebei Changshan Biochem Pharma Industry Peers by Asset Resilience Ratio

Compare Hebei Changshan Biochem Pharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Hebei Changshan Biochem Pharma (None–None)

The table below shows the annual Asset Resilience Ratio data for Hebei Changshan Biochem Pharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About Hebei Changshan Biochem Pharma

SHE:300255 China Biotechnology

Market Cap

$3.10 Billion

CN¥21.19 Billion CNY

Market Cap Rank

#4834 Global

#807 in China

Share Price

CN¥23.06

Change (1 day)

+0.70%

52-Week Range

CN¥21.95 - CN¥69.80

All Time High

CN¥69.80